| |
Coffee use |
|
|
| |
|
Null |
|
Weekly |
|
Daily |
Trend |
Interaction |
| Genotype |
na |
ORab |
na |
OR (95% CI)b |
na |
OR (95%CI)b |
P |
P |
| CYP1A2*1C |
|
|
|
|
|
|
|
|
| GG |
25/88 |
1.00 (referent) |
21/171 |
0.39 (0.20-0.76) |
55/603 |
0.29 (0.16-0.51) |
<0.0001 |
0.07 |
| GA + AA |
12/93 |
1.00 (referent) |
18/128 |
1.26 (0.55-2.90) |
47/426 |
0.89 (0.41-1.90) |
0.55 |
|
| CYP1A2*1F |
|
|
|
|
|
|
|
|
| AA |
12/86 |
1.00 (referent) |
18/118 |
1.03 (0.43-2.44) |
41/450 |
0.46 (0.20-1.03) |
0.02 |
0.61 |
| CA + CC |
25/98 |
1.00 (referent) |
22/181 |
0.48 (0.25-0.92) |
61/579 |
0.42 (0.24-0.74) |
0.006 |
|
OR, odds ratio; CI, confidence interval.
aNumber of cases/controls.
bAdjusted for age, hospital, rank in the Self-Defense Forces, cigarette smoking, leisure-time physical activity, body mass index, current use of alcoholic beverages (sake,
shochu, beer, whisky and wine), past alcohol use and green tea intake. |
